27 results
8-K
EX-10.2
NBSE
NeuBase Therapeutics Inc
30 Jun 23
NeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
4:21pm
or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata), including laws relating
8-K
EX-10.1
NBSE
NeuBase Therapeutics Inc
30 Jun 23
NeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
4:21pm
or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata), including laws
8-K
EX-99.1
NBSE
NeuBase Therapeutics Inc
22 May 23
Regulation FD Disclosure
7:00am
NEUBASE THERAPEUTICS, INC. 12 Stealth Editors™ are Non-Immunogenic in Human PBMCs PBS Water LPS Imiquimod Stealth Editor 0 10000 20000 30000 IL-8 pg … /mL PBS Water LPS Imiquimod Stealth Editor 0 100 200 300 400 500 5000 10000 15000 20000 25000 30000 IL-6 pg/mL PBS Water LPS Imiquimod Stealth Editor
8-K
EX-1.1
a30g 46ba
27 Aug 21
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.2
s2ikv30zxotx2z ojgks
8 Jun 21
Regulation FD Disclosure
2:01pm
8-K
EX-1.1
bz1z2cryxe9m
22 Apr 21
NeuBase Therapeutics Announces Pricing of $40 Million Public Offering of Common Stock
9:33am
8-K
EX-1.1
1w8js
29 Apr 20
NeuBase Therapeutics Announces Pricing of $31,500,000 Public Offering of Common Stock
12:00am
8-K/A
EX-99.1
r24hv at5yfj7
3 Apr 20
Financial Statements and Exhibits
5:10pm
8-K
EX-99.2
rc9hzicr4
31 Mar 20
NeuBase Therapeutics Announces Positive, Preclinical Data Validating its Novel Genetic Therapy PATrOL™ Platform
9:10am
8-K
EX-2.1
vh7j8j2g ox8
3 Jan 19
Entry into a Material Definitive Agreement
5:29pm
8-K
EX-99.2
ubxzd
3 Jan 19
Entry into a Material Definitive Agreement
5:29pm
425
EX-2.1
iv5sdcljvi3 gqklk17
3 Jan 19
Business combination disclosure
5:28pm
425
EX-99.2
nessmtjba pffoair7w
3 Jan 19
Business combination disclosure
5:28pm